Mesoblast Reports GAAP EPS of -$0.04 and Revenue of $120.25M in Q4
Mesoblast Limited (NASDAQ:MESO) reported a fiscal year GAAP earnings per share (EPS) loss of -$0.04, which beat analysts' expectations by $0.08. However, the company's revenue came in at $120.25 million for Q4 2026, missing estimates by $65.62 million despite a significant year-over-year increase of nearly 600%. The results reflect strong growth but also highlight challenges in meeting financial forecasts. The earnings report follows recent regulatory milestones, including FDA approval for a new potency assay for Ryoncil and participation in an FDA-Duke-Margolis workshop focused on evidence standards for rare diseases. These developments may support future product approvals or market expansion efforts. Mesoblast's performance is being analyzed within the broader context of its strategic initiatives and financial health, with Seeking Alpha’s Quant Rating offering additional insights into investor sentiment.
Tickers: $MESO
Topics: Earnings FDA Approval Pharmaceuticals